|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIP12 |
Gene summary for TRIP12 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIP12 | Gene ID | 9320 |
| Gene name | thyroid hormone receptor interactor 12 | |
| Gene Alias | MRD49 | |
| Cytomap | 2q36.3 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q14669 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9320 | TRIP12 | CA_HPV_1 | Human | Cervix | CC | 1.91e-02 | 4.30e-02 | 0.0264 |
| 9320 | TRIP12 | CCI_3 | Human | Cervix | CC | 9.20e-05 | 6.17e-01 | 0.516 |
| 9320 | TRIP12 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.16e-17 | -5.64e-01 | 0.0155 |
| 9320 | TRIP12 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.90e-10 | -5.95e-01 | -0.1207 |
| 9320 | TRIP12 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.89e-04 | -3.52e-01 | -0.1001 |
| 9320 | TRIP12 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.43e-02 | -3.46e-01 | -0.0179 |
| 9320 | TRIP12 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.58e-04 | -4.31e-01 | 0.096 |
| 9320 | TRIP12 | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.43e-02 | -5.42e-01 | 0.0528 |
| 9320 | TRIP12 | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.94e-04 | -3.93e-01 | 0.0338 |
| 9320 | TRIP12 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.19e-07 | -3.79e-01 | 0.0674 |
| 9320 | TRIP12 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.00e-03 | -3.16e-01 | 0.294 |
| 9320 | TRIP12 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 3.16e-02 | -4.62e-01 | 0.2585 |
| 9320 | TRIP12 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.28e-05 | -3.42e-01 | 0.3005 |
| 9320 | TRIP12 | F007 | Human | Colorectum | FAP | 1.88e-02 | -2.42e-01 | 0.1176 |
| 9320 | TRIP12 | A001-C-207 | Human | Colorectum | FAP | 1.87e-03 | -2.05e-01 | 0.1278 |
| 9320 | TRIP12 | A015-C-203 | Human | Colorectum | FAP | 5.88e-38 | -4.10e-01 | -0.1294 |
| 9320 | TRIP12 | A015-C-204 | Human | Colorectum | FAP | 1.11e-06 | -2.61e-01 | -0.0228 |
| 9320 | TRIP12 | A014-C-040 | Human | Colorectum | FAP | 9.46e-05 | -3.68e-01 | -0.1184 |
| 9320 | TRIP12 | A002-C-201 | Human | Colorectum | FAP | 1.68e-16 | -3.99e-01 | 0.0324 |
| 9320 | TRIP12 | A002-C-203 | Human | Colorectum | FAP | 2.74e-08 | -2.24e-01 | 0.2786 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
| GO:003139610 | Cervix | CC | regulation of protein ubiquitination | 59/2311 | 210/18723 | 5.90e-10 | 7.51e-08 | 59 |
| GO:00002097 | Cervix | CC | protein polyubiquitination | 58/2311 | 236/18723 | 1.57e-07 | 7.41e-06 | 58 |
| GO:003139710 | Cervix | CC | negative regulation of protein ubiquitination | 28/2311 | 83/18723 | 3.32e-07 | 1.35e-05 | 28 |
| GO:190332110 | Cervix | CC | negative regulation of protein modification by small protein conjugation or removal | 29/2311 | 95/18723 | 2.15e-06 | 6.55e-05 | 29 |
| GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
| GO:00459955 | Cervix | CC | regulation of embryonic development | 19/2311 | 64/18723 | 1.78e-04 | 2.09e-03 | 19 |
| GO:20010209 | Cervix | CC | regulation of response to DNA damage stimulus | 46/2311 | 219/18723 | 1.92e-04 | 2.23e-03 | 46 |
| GO:00310565 | Cervix | CC | regulation of histone modification | 33/2311 | 152/18723 | 7.97e-04 | 7.00e-03 | 33 |
| GO:00510528 | Cervix | CC | regulation of DNA metabolic process | 65/2311 | 359/18723 | 9.25e-04 | 7.84e-03 | 65 |
| GO:00705343 | Cervix | CC | protein K63-linked ubiquitination | 14/2311 | 56/18723 | 6.93e-03 | 3.74e-02 | 14 |
| GO:1903320 | Colorectum | AD | regulation of protein modification by small protein conjugation or removal | 86/3918 | 242/18723 | 9.43e-08 | 4.65e-06 | 86 |
| GO:0051052 | Colorectum | AD | regulation of DNA metabolic process | 116/3918 | 359/18723 | 2.47e-07 | 1.00e-05 | 116 |
| GO:0031396 | Colorectum | AD | regulation of protein ubiquitination | 72/3918 | 210/18723 | 4.50e-06 | 1.21e-04 | 72 |
| GO:0000209 | Colorectum | AD | protein polyubiquitination | 78/3918 | 236/18723 | 8.71e-06 | 2.06e-04 | 78 |
| GO:0031397 | Colorectum | AD | negative regulation of protein ubiquitination | 34/3918 | 83/18723 | 2.66e-05 | 5.04e-04 | 34 |
| GO:2001020 | Colorectum | AD | regulation of response to DNA damage stimulus | 71/3918 | 219/18723 | 4.38e-05 | 7.65e-04 | 71 |
| GO:1903321 | Colorectum | AD | negative regulation of protein modification by small protein conjugation or removal | 37/3918 | 95/18723 | 4.49e-05 | 7.83e-04 | 37 |
| GO:0006282 | Colorectum | AD | regulation of DNA repair | 42/3918 | 130/18723 | 1.57e-03 | 1.32e-02 | 42 |
| GO:0045995 | Colorectum | AD | regulation of embryonic development | 24/3918 | 64/18723 | 1.72e-03 | 1.43e-02 | 24 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
| hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
| hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
| hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
| hsa041202 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
| hsa041203 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
| hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
| hsa041205 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
| hsa041206 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
| hsa041207 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
| hsa041208 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
| hsa041209 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
| hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
| hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
| hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
| hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
| hsa0412021 | Liver | Cirrhotic | Ubiquitin mediated proteolysis | 72/2530 | 142/8465 | 1.32e-07 | 1.97e-06 | 1.21e-06 | 72 |
| hsa0412031 | Liver | Cirrhotic | Ubiquitin mediated proteolysis | 72/2530 | 142/8465 | 1.32e-07 | 1.97e-06 | 1.21e-06 | 72 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIP12 | SNV | Missense_Mutation | novel | c.802N>G | p.Lys268Glu | p.K268E | Q14669 | protein_coding | tolerated_low_confidence(0.16) | possibly_damaging(0.885) | TCGA-05-5425-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | gefitinib | PD |
| TRIP12 | SNV | Missense_Mutation | c.205N>G | p.Arg69Gly | p.R69G | Q14669 | protein_coding | tolerated_low_confidence(0.13) | benign(0) | TCGA-49-AAR0-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TRIP12 | SNV | Missense_Mutation | c.2567N>T | p.Thr856Ile | p.T856I | Q14669 | protein_coding | tolerated(0.11) | benign(0.086) | TCGA-50-5930-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxotere | PD | |
| TRIP12 | SNV | Missense_Mutation | c.2569N>T | p.Ser857Cys | p.S857C | Q14669 | protein_coding | deleterious(0.05) | benign(0.439) | TCGA-53-7624-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
| TRIP12 | SNV | Missense_Mutation | c.359C>A | p.Pro120Gln | p.P120Q | Q14669 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-53-7626-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unspecific | Cisplatin | PD | |
| TRIP12 | SNV | Missense_Mutation | c.65N>C | p.Gly22Ala | p.G22A | Q14669 | protein_coding | tolerated_low_confidence(0.47) | benign(0.007) | TCGA-55-1595-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TRIP12 | SNV | Missense_Mutation | c.2503N>T | p.Asn835Tyr | p.N835Y | Q14669 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-69-7979-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TRIP12 | SNV | Missense_Mutation | novel | c.4381N>A | p.Gly1461Ser | p.G1461S | Q14669 | protein_coding | tolerated(0.41) | benign(0.133) | TCGA-73-4666-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| TRIP12 | SNV | Missense_Mutation | c.2966C>T | p.Thr989Ile | p.T989I | Q14669 | protein_coding | tolerated(0.17) | benign(0.052) | TCGA-91-6829-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TRIP12 | SNV | Missense_Mutation | novel | c.17N>G | p.Asn6Ser | p.N6S | Q14669 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.931) | TCGA-91-8497-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |